VivoSeq
Other

Overactive Bladder

114

Pipeline Programs↗

22

Active Trials↗

32

Companies Involved↗

Overactive Bladder is a highly competitive landscape with 114 programs across 32 companies. The most active players are Imbrium Therapeutics, Takeda, Kissei Pharmaceutical Co., Ltd.. 33 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

30/100

Mech. Concentration

12/100

Completion Rate

90/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Imbrium Therapeutics

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1K

Kissei Pharmaceutical Co., Ltd.

1 program

Phase 2V

Velicept Therapeutics, Inc.

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 2V

Vyne Therapeutics Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical17

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Platelet Rich Plasma

Zagazig University

Imidafenacin

Astellas

Vibegron

Sumitomo Pharma America, Inc.

Propiverine

Astellas

Phase 110

Macrobid

Mylan Pharmaceuticals Inc

Meditoxin

Medy-Tox

V117957

Imbrium Therapeutics

Prophylactic Antibiotic

Merck & Co.

Hmaxi-K

Urovant Sciences GmbH

Phase 232

Desmopressin

Ferring

Gefapixant

Merck & Co.

KUC-7483

Kissei Pharmaceutical Co., Ltd.

UK-369,003

Pfizer

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 322

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Gabapentin

Viatris Specialty LLC

YM178

Astellas

Botox

AbbVie

Vesicare

Astellas

Approved33

Warfarin

Abbott

Tolterodine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Oxybutynin

Wim Janssens

Fesoterodine

Pfizer

Darifenacin

AbbVie

Analysis

Trial Status

258

clinical trials

Completed188 · 73%
Unknown status26 · 10%
Terminated16 · 6%
Recruiting13 · 5%
Withdrawn6 · 2%
Not yet recruiting6 · 2%
Other3 · 1%

Clinical Trials

Trial Activity

258 trials

Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes
Recruiting·MMackay Medical College·N/A·NCT07025642·60 enrolled
Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
Recruiting·MMansoura University·Phase 4·NCT07416968·480 enrolled
HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
Recruiting·FFar Eastern Memorial Hospital·N/A·NCT05280028·100 enrolled
Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
Recruiting·—·N/A·NCT07025044·40 enrolled
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Recruiting·WWalter Reed National Military Medical Center·Phase 4·NCT05221021·152 enrolled
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
Recruiting·MMansoura University·Phase 4·NCT07473310·70 enrolled
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Recruiting·NNorthwestern University·Phase 2/3·NCT05878951·80 enrolled
Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial
Recruiting·—·N/A·NCT07184307·48 enrolled
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
Recruiting·WWalter Reed National Military Medical Center·Phase 4·NCT04020510·184 enrolled
Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
Recruiting·—·N/A·NCT05798403·204 enrolled
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
Recruiting·MMackay Memorial Hospital·Phase 4·NCT06479720·300 enrolled
Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease
Recruiting·ZZhujiang Hospital·Phase 1·NCT05997043·60 enrolled
Sacral Neuromodulation for Male Overactive Bladder
Recruiting·AAxonics, Inc.·Preclinical·NCT06511141·150 enrolled
Treatment of Overactive Bladder With Anticholinergic Agents
Active, not recruiting·SSehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital·N/A·NCT07046156·120 enrolled
Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study
Active, not recruiting·MMahmoud Mohamed Farag Ali·Preclinical·NCT07693192·60 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)